Efficacy and Safety of Biologic Therapies for Treatment of Psoriasis: A Systematic Review and Observational Meta-Analysis
October 2024
in “
QJM
”
TLDR IL-12/23 inhibitors are more effective and have fewer common side effects than anti-TNF alpha for treating psoriasis.
This systematic review and meta-analysis compared the efficacy and safety of biologic therapies, specifically anti-TNF alpha and anti IL12/23, in treating moderate to severe psoriasis. The study found that IL-12/23 inhibitors have a higher probability of achieving a PASI 75 response at year 1 (84%) compared to anti-TNF alpha (76.18%). Over longer periods, IL-12/23 inhibitors maintained stable efficacy, with a PASI 75 rate of about 80% at years 2, 3, and 5, and 91% at year 4. Both therapies showed no significant difference in the risk of serious infections or malignancy rates. However, anti-TNF alpha was associated with a higher rate of common adverse events compared to IL-12/23 inhibitors. The study highlights the superior efficacy of IL-12/23 inhibitors in achieving sustained psoriasis improvement with a comparable safety profile to anti-TNF alpha.
